Pharmaceuticals, Biotechnology and Life Sciences
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Low levels of breast cancer factor 1 (BRCA1) protein in the brain may contribute to dementia, according to results of a National Institutes of Health (NIH)-funded study, published in Nature Communications.
Janssen Biotech, Inc. and Janssen-Cilag International NV (Janssen) are seeking approval from the U.S. and European authorities for Chron’s disease drug Stelara.
Horizon Pharma and its affiliate, Horizon Therapeutics, has gotten the European Commission’s (EC’s) approval for Ravicti – glycerol phenylbutyrate – Oral Liquid for use as an adjunctive therapy for chronic management patients with six subtypes of Urea Cycle Disorders (UCDs).
When HIV-positive patients first came to seek treatment at the rural Uthungulu district health clinic in South Africa’s eastern KwaZulu-Natal province in 1998, their records were kept in brown folders, the colour designated for the disease.
Boston-based PureTech Health plc has launched a Scientific Advisory Board (SAB) of distinguished scientists and physicians, and the expansion of PureTech’s senior team.
Allergy Therapeutics, a UK-based specialist in allergy vaccines, has completed randomization with 364 patients entered into the PQBirch204 double-blind, placebo-controlled dose selection study for the specific subcutaneous immunotherapy (SCIT), Pollinex Quattro Birch.
Cipla launching low-dose Efavirenz 400 mg HIV infection therapy
Teva and Takeda are forming a new joint venture to operate in Japan